Spain's Oryzon Genomics' Q1 net loss widens on higher R&D costs

ORYZON Genomics SA

14/05/2026 15:57

Overview

Spanish Biopharma firm's reported Q1 net loss widened as R&D and admin expenses rose

Company ended Q1 with $25.4 mln in cash and equivalents

Outlook

Company expects initial clinical updates from the RESTORE sickle cell disease trial by year-end

Oryzon preparing for FDA protocol resubmission for PORTICO-2 Phase III trial in aggression in BPD

Company anticipates presenting updated clinical data from ALICE-2 and FRIDA studies at EHA 2026

Result Drivers

CLINICAL TRIAL EXPANSION - Increased R&D spending driven by ongoing and new clinical trials for iadademstat and vafidemstat

Company press release: ID:nGNX1nhm5H

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$1.99 mln
Q1 Income From Operations
-$6.67 mln
Q1 Operating Expenses
$6.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Oryzon Genomics SA is €6.00, about 118% above its May 13 closing price of €2.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)